
Eloxx loss widens to $5.5 million in Q3
Key points
- Eloxx Pharmaceuticals (NASDAQ:ELOX) reported a third-quarter 2026 net loss of $5.543 million, compared with $351,000 a year earlier.
- Cash and cash equivalents totalled $56.264 million at September 30, with management expecting funding to last into 2028.
- Eloxx dosed the first two patients in its Phase 2b EXACT Alport syndrome trial and received FDA clearance to open U.S. sites for its EXPRESS ADPKD study.
Eloxx Pharmaceuticals (NASDAQ:ELOX) reported a third-quarter 2026 net loss of $5.543 million, compared with $351,000 a year earlier, as spending on clinical development increased.
The comparison reflects a prior-year net research and development credit of $250,000, while third-quarter 2026 research and development expenses reached $4.028 million and general and administrative expenses increased to $1.925 million.
Loss per share narrowed to $0.49 from $0.58, partly reflecting an increase in weighted-average shares to approximately 11.4 million from 604,278, while the company reported $56.264 million in cash and expects funding to support operations into 2028.
Following the announcement, Eloxx shares were up 5.63% at $13.89 in premarket trading at 7:41 a.m. ET on November 16.
The EXACT Phase 2b trial is evaluating exaluren in patients with Alport syndrome caused by nonsense mutations, with the company expecting 16-week topline results in mid-2027 and final 32-week data by the end of 2027.
Eloxx also finalized its 52-week EXPRESS Phase 2 study for nonsense mutation autosomal dominant polycystic kidney disease, expects first patient dosing in the third quarter of 2027 and anticipates topline results in the first half of 2029, following FDA clearance of its investigational new drug application.
Frequently asked questions
More from United States
POET revenue skyrockets 244% to $1.03 million
Prelude Therapeutics loss narrows to $12.5 million
Invivyd revenue accelerates 18% to $15.4 million
Blackstone Digital Trust reports $5 billion Amazon deal
Granite completes two deals targeting $175 million revenue
TELUS reviews Québecor's C$19.45 takeover proposal

